The most common side effects in clinical studies of Flexeril.
The most common adverse reactions that have been reported with a frequency of ≥ 3% are: dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and drowsiness.
Additional adverse reactions that have been observed in clinical studies and in post-marketing use. Below you can see adverse reactions that were recorded in clinical studies or post-marketing use of cyclobenzaprine with prolonged action, immediate release cyclobenzaprine or tricyclic preparations.
In the post-registration monitoring program for immediate-release cyclobenzaprine, frequent adverse reactions are: drowsiness, dry mouth and dizziness, and adverse reactions that occurred in 1-3% of patients are: fatigue / fatigue, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness and confusion.
Below adverse reactions that were recorded during post-marketing use of prolonged-release cyclobenzaprine or immediate release cyclobenzaprine in clinical studies (<1%) or during post-marketing use of other tricyclic preparations:
Common disorders: fainting, malaise, chest pain, swelling.
Cardiovascular system: tachycardia, arrhythmia, vasodilation, palpitations, arterial hypotension, arterial hypertension, myocardial infarction, blockade of cardiac conduction, stroke.
Digestive system: vomiting, anorexia, diarrhea, abdominal pain, gastritis, thirst, flatulence, swelling of the tongue, abnormal liver function and rare cases of hepatitis, jaundice and cholestasis, paralytic intestinal obstruction, discoloration of the tongue, stomatitis, swelling of the parotid salivary gland .
Endocrine system: inadequate secretion syndrome.
Blood and lymphatic system: purpura, bone marrow suppression, leukopenia, eosinophilia, thrombocytopenia.
Hypersensitivity reactions: anaphylactic shock, angioedema, pruritus, swelling of the face, urticaria, rash.
Metabolic, nutritional and immune disorders: increase or decrease in blood sugar levels, increase or loss of body weight.
Musculoskeletal system: local muscle weakness, myalgia.
Nervous system: convulsive seizures, ataxia, vertigo, dysarthria, tremor, hypertension, convulsions, muscle twitching, disorientation, insomnia, depressed mood, unusual sensations, anxiety, agitation, psychosis, abnormal thoughts and dreams, hallucinations, unrest , paresthesias, diplopia, serotonin syndrome, neuroleptic malignant syndrome, decreased or increased libido, gait disturbance, delirium, aggressive behavior, paranoia, peripheral neuropathy.
Respiratory system: shortness of breath.
Skin and subcutaneous tissues: sweating, photosensitivity, alopecia.
Kidneys and urinary tract: increase and / or decrease the frequency of urination, impaired urination, dilatation of the urinary tract, impotence, testicular edema, gynecomastia, breast augmentation, galactorrhea.